Nextgeneration probiotics targeting Clostridium difficile through precursor-directed antimicrobial biosynthesis

Infection and Immunity

Volumn 85, Issue 10, 2017, Pages

  Spinler, Jennifer K ^a,b   Auchtung, Jennifer ^a   Brown, Aaron ^a,b   Boonma, Prapaporn ^a,b   Oezguen, Numan ^a,b   Ross, Caná L ^a,b   Luna, Ruth Ann ^a,b   Runge, Jessica ^a,b   Versalovic, James ^a,b   Peniche, Alex ^c   Dann, Sara M ^c   Britton, Robert A ^a   Haag, Anthony ^a,b   Savidge, Tor C ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Antimicrobial resistance; Clostridium difficile; Lactobacillus reuteri; Next generation probiotics; Reuterin

Indexed keywords

CLINDAMYCIN; FIDAXOMICIN; GLYCEROL; METRONIDAZOLE; PROBIOTIC AGENT; RNA 16S; VANCOMYCIN; 3-HYDROXYPROPIONALDEHYDE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; GLYCERALDEHYDE; PROPANE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC BIOSYNTHESIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL SURVIVAL; BIOSYNTHESIS; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; EX VIVO STUDY; FECES MICROFLORA; GENE LOCUS; GENE MUTATION; IN VITRO STUDY; INTESTINE FLORA; LACTOBACILLUS REUTERI; METABOLOMICS; MICROBIAL COMMUNITY; MINIMUM INHIBITORY CONCENTRATION; MULTIDIMENSIONAL SCALING; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CLOSTRIDIUM INFECTIONS; DRUG DEVELOPMENT; DRUG EFFECTS; FECES; FERMENTATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PROCEDURES;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; FECES; FERMENTATION; GASTROINTESTINAL MICROBIOME; GLYCERALDEHYDE; GLYCEROL; HUMANS; LACTOBACILLUS REUTERI; METABOLOMICS; PROBIOTICS; PROPANE; VANCOMYCIN;

EID: 85029763028     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00303-17     Document Type: Article

References (80)

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention, Atlanta, GA
2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 825-834. https://doi.org/10.1056/NEJMoa1408913
3. Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC. 2016. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis 16:303. https://doi.org/10.1186/s12879-016-1610-3
4. Garey KW, Sethi S, Yadav Y, DuPont HL. 2008. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70: 298-304. https://doi.org/10.1016/j.jhin.2008.08.012
5. Kelly CP. 2012. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6):S21-S27. https://doi.org/10.1111/1469-0691.12046
6. McFarland LV, Elmer GW, Surawicz CM. 2002. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97:1769-1775. https://doi.org/10.1111/j.1572-0241.2002.05839.x
7. Ofosu A. 2016. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol 29:147-154
8. Food and Drug Administration (FDA). Guidance for industry. Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. FDA, Rockville, MD
9. Task Force for Combatting Antibitotic-Resistant Bacteria. 2015. National action plan for combating antibiotic-resistant bacteria. The White House, Washington, DC
10. McFarland LV. 2016. Therapies on the horizon for Clostridium difficile infections. Expert Opin Investig Drugs 25:541-555. https://doi.org/10.1517/13543784.2016.1161025
11. Bakken JS. 2014. Staggered and tapered antibiotic withdrawal with administration of kefir for recurrent Clostridium difficile infection. Clin Infect Dis 59:858-861. https://doi.org/10.1093/cid/ciu429
12. Maziade PJ, Andriessen JA, Pereira P, Currie B, Goldstein EJ. 2013. Impact of adding prophylactic probiotics to a bundle of standard preventative measures for Clostridium difficile infections: enhanced and sustained decrease in the incidence and severity of infection at a community hospital. Curr Med Res Opin 29:1341-1347. https://doi.org/10.1185/ 03007995.2013.833501
13. Maziade PJ, Pereira P, Goldstein EJ. 2015. A decade of experience in primary prevention of Clostridium difficile infection at a community hospital using the probiotic combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis 60(Suppl 2):S144-S147. https://doi.org/10.1093/ cid/civ178
14. Spinler JK, Ross CL, Savidge TC. 2016. Probiotics as adjunctive therapy for preventing Clostridium difficile infection-what are we waiting for? Anaerobe 41:51-57. https://doi.org/10.1016/j.anaerobe.2016.05.007
15. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31:431-455. https://doi.org/10.1086/651706
16. Sinclair A, Xie X, Saab L, Dendukuri N. 2016. Lactobacillus probiotics in the prevention of diarrhea associated with Clostridium difficile: a systematic review and Bayesian hierarchical meta-analysis. CMAJ Open 4:E706-E718. https://doi.org/10.9778/cmajo.20160087
17. Pamer EG. 2016. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352:535-538. https://doi.org/10.1126/science.aad9382
18. Jose NM, Bunt CR, Hussain MA. 2015. Implications of antibiotic resistance in probiotics. Food Rev Int 31:52-62. https://doi.org/10.1080/87559129.2014.961075
19. Vollenweider S, Grassi G, Konig I, Puhan Z. 2003. Purification and structural characterization of 3-hydroxypropionaldehyde and its derivatives. J Agric Food Chem 51:3287-3293. https://doi.org/10.1021/jf021086d
20. Casas IA, Dobrogosz WJ. 2000. Validation of the probiotic concept: Lactobacillus reuteri confers broad-spectrum protection against disease in humans and animals. Microb Ecol Health Dis 12:247-285
21. Cleusix V, Lacroix C, Vollenweider S, Duboux M, Le Blay G. 2007. Inhibitory activity spectrum of reuterin produced by Lactobacillus reuteri against intestinal bacteria. BMC Microbiol 7:101. https://doi.org/10.1186/ 1471-2180-7-101
22. Morita H, Toh H, Fukuda S, Horikawa H, Oshima K, Suzuki T, Murakami M, Hisamatsu S, Kato Y, Takizawa T, Fukuoka H, Yoshimura T, Itoh K, O'Sullivan DJ, McKay LL, Ohno H, Kikuchi J, Masaoka T, Hattori M. 2008. Comparative genome analysis of Lactobacillus reuteri and Lactobacillus fermentum reveal a genomic island for reuterin and cobalamin production. DNA Res 15:151-161. https://doi.org/10.1093/dnares/dsn009
23. Santos F, Vera JL, van der Heijden R, Valdez G, de Vos WM, Sesma F, Hugenholtz J. 2008. The complete coenzyme B12 biosynthesis gene cluster of Lactobacillus reuteri CRL1098. Microbiology 154:81-93. https:// doi.org/10.1099/mic.0.2007/011569-0
24. Sriramulu DD, Liang M, Hernandez-Romero D, Raux-Deery E, Lunsdorf H, Parsons JB, Warren MJ, Prentice MB. 2008. Lactobacillus reuteri DSM 20016 produces cobalamin-dependent diol dehydratase in metabolosomes and metabolizes 1,2-propanediol by disproportionation. J Bacteriol 190:4559-4567. https://doi.org/10.1128/JB.01535-07
25. Jacobsen CN, Rosenfeldt Nielsen V, Hayford AE, Moller PL, Michaelsen KF, Paerregaard A, Sandstrom B, Tvede M, Jakobsen M. 1999. Screening of probiotic activities of forty-seven strains of Lactobacillus spp. by in vitro techniques and evaluation of the colonization ability of five selected strains in humans. Appl Environ Microbiol 65:4949-4956
26. Goldstein EJ, Tyrrell KL, Citron DM. 2015. Lactobacillus species: taxonomic complexity and controversial susceptibilities. Clin Infect Dis 60(Suppl 2):S98-S107. https://doi.org/10.1093/cid/civ072
27. Snydman DR, McDermott LA, Jacobus NV, Thorpe C, Stone S, Jenkins SG, Goldstein EJ, Patel R, Forbes BA, Mirrett S, Johnson S, Gerding DN. 2015. U.S.-based national sentinel surveillance study for the epidemiology of Clostridium difficile-associated diarrheal isolates and their susceptibility to fidaxomicin. Antimicrob Agents Chemother 59:6437-6443. https://doi.org/10.1128/AAC.00845-15
28. Boonma P, Spinler JK, Venable SF, Versalovic J, Tumwasorn S. 2014. Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol 14:177. https://doi.org/10.1186/1471-2180-14-177
29. Sears P, Crook DW, Louie TJ, Miller MA, Weiss K. 2012. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis 55(Suppl 2):S116-S120. https://doi.org/10.1093/cid/ cis337
30. Spinler JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DM, Mistretta TA, Devaraj S, Walter J, Versalovic J, Highlander SK. 2014. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol 6:1772-1789. https://doi.org/10.1093/gbe/ evu137
31. Santos F, Spinler JK, Saulnier DM, Molenaar D, Teusink B, de Vos WM, Versalovic J, Hugenholtz J. 2011. Functional identification in Lactobacillus reuteri of a PocR-like transcription factor regulating glycerol utilization and vitamin B12 synthesis. Microb Cell Fact 10:55. https://doi.org/ 10.1186/1475-2859-10-55
32. Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. 2008. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe 14:166-171. https://doi.org/10.1016/j.anaerobe.2008.02.001
33. Schaefer L, Auchtung TA, Hermans KE, Whitehead D, Borhan B, Britton RA. 2010 The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. Microbiology 156:1589-1599. https://doi.org/10.1099/mic.0.035642-0
34. Talarico TL, Dobrogosz WJ. 1990. Purification and characterization of glycerol dehydratase from Lactobacillus reuteri. Appl Environ Microbiol 56:1195-1197
35. Robinson CD, Auchtung JM, Collins J, Britton RA. 2014. Epidemic Clostridium difficile strains demonstrate increased competitive fitness compared to nonepidemic isolates. Infect Immun 82:2815-2825. https://doi.org/10.1128/IAI.01524-14
36. Bartlett JG. 1981. Antimicrobial agents implicated in Clostridium difficile toxin-associated diarrhea of colitis. Johns Hopkins Med J Suppl 149:6-9
37. Schubert AM, Rogers MA, Ring C, Mogle J, Petrosino JP, Young VB, Aronoff DM, Schloss PD. 2014. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. mBio 5:e01021-14. https://doi.org/10.1128/mBio.01021-14
38. Biebl H, Menzel K, Zeng AP, Deckwer WD. 1999. Microbial production of 1,3-propanediol. Appl Microbiol Biotechnol 52:289-297. https://doi.org/ 10.1007/s002530051523
39. Kolodziej M, Szajewska H. 2017. Lactobacillus reuteri DSM 17938 in the prevention of antibiotic-associated diarrhoea in children: protocol of a randomised controlled trial. BMJ Open 7:e013928. https://doi.org/10.1136/bmjopen-2016-013928
40. Dinleyici EC, Dalgic N, Guven S, Metin O, Yasa O, Kurugol Z, Turel O, Tanir G, Yazar AS, Arica V, Sancar M, Karbuz A, Eren M, Ozen M, Kara A, Vandenplas Y. 2015. Lactobacillus reuteri DSM 17938 shortens acute infectious diarrhea in a pediatric outpatient setting. J Pediatr (Rio J) 91:392-396. https://doi.org/10.1016/j.jped.2014.10.009
41. Dinleyici EC, Vandenplas Y. 2014. Lactobacillus reuteri DSM 17938 effectively reduces the duration of acute diarrhoea in hospitalised children. Acta Paediatr 103:e300-e305. https://doi.org/10.1111/apa.12617
42. Shornikova AV, Casas IA, Isolauri E, Mykkanen H, Vesikari T. 1997. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children. J Pediatr Gastroenterol Nutr 24:399-404. https://doi.org/10.1097/00005176-199704000-00008
43. Cimperman L, Bayless G, Best K, Diligente A, Mordarski B, Oster M, Smith M, Vatakis F, Wiese D, Steiber A, Katz J. 2011. A randomized, doubleblind, placebo-controlled pilot study of Lactobacillus reuteri ATCC 55730 for the prevention of antibiotic-associated diarrhea in hospitalized adults. J Clin Gastroenterol 45:785-789. https://doi.org/10.1097/MCG.0b013e3182166a42
44. Tubelius P, Stan V, Zachrisson A. 2005. Increasing work-place healthiness with the probiotic Lactobacillus reuteri: a randomised, double-blind placebo-controlled study. Environ Health 4:25. https://doi.org/10.1186/ 1476-069X-4-25
45. Cleusix V, Lacroix C, Vollenweider S, Le Blay G. 2008. Glycerol induces reuterin production and decreases Escherichia coli population in an in vitro model of colonic fermentation with immobilized human feces. FEMS Microbiol Ecol 63:56-64. https://doi.org/10.1111/j.1574-6941.2007.00412.x
46. Vankerckhoven VV, Van Autgaerden T, Geert H, Vancanneyt M, Swings J, Goossens H. 2004. Establishment of the PROSAFE collection of probiotic and human lactic acid bacteria. Microb Ecol Health Dis 16:131-136. https://doi.org/10.1080/08910600410032349
47. Rosander A, Connolly E, Roos S. 2008. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol 74:6032-6040. https://doi.org/10.1128/AEM.00991-08
48. Cox G, Wright GD. 2013. Intrinsic antibiotic resistance: mechanisms, origins, challenges and solutions. Int J Med Microbiol 303:287-292. https://doi.org/10.1016/j.ijmm.2013.02.009
49. Klein G, Hallmann C, Casas IA, Abad J, Louwers J, Reuter G. 2000. Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridization methods. J Appl Microbiol 89:815-824. https://doi.org/10.1046/j.1365-2672.2000.01187.x
50. van Pijkeren JP, Britton RA. 2012. High efficiency recombineering in lactic acid bacteria. Nucleic Acids Res 40:e76. https://doi.org/10.1093/ nar/gks147
51. Ammor MS, Florez AB, Mayo B. 2007. Antibiotic resistance in nonenterococcal lactic acid bacteria and bifidobacteria. Food Microbiol 24:559-570. https://doi.org/10.1016/j.fm.2006.11.001
52. Klare I, Konstabel C, Werner G, Huys G, Vankerckhoven V, Kahlmeter G, Hildebrandt B, Muller-Bertling S, Witte W, Goossens H. 2007. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antmicrob Chemother 59:900-912. https://doi.org/10.1093/jac/dkm035
53. Egervarn M, Danielsen M, Roos S, Lindmark H, Lindgren S. 2007. Antibiotic susceptibility profiles of Lactobacillus reuteri and Lactobacillus fermentum. J Food Prot 70:412-418. https://doi.org/10.4315/0362-028X-70.2.412
54. Venugopal AA, Johnson S. 2012. Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 54:568-574. https://doi.org/10.1093/cid/cir830
55. Jaeger KE, Ransac S, Dijkstra BW, Colson C, van Heuvel M, Misset O. 1994. Bacterial lipases. FEMS Microbiol Rev 15:29-63. https://doi.org/10.1111/ j.1574-6976.1994.tb00121.x
56. Kato T, Hayashi Y, Inoue K, Yuasa H. 2005. Glycerol absorption by Na+-dependent carrier-mediated transport in the closed loop of the rat small intestine. Biol Pharm Bull 28:553-555
57. Fujimoto N, Inoue K, Ohgusu Y, Hayashi Y, Yuasa H. 2007. Enhanced uptake of glycerol by butyrate treatment in HCT-15 human colon cancer cell line. Drug Metab Pharmacokinet 22:195-198. https://doi.org/10.2133/dmpk.22.195
58. De Weirdt R, Possemiers S, Vermeulen G, Moerdijk-Poortvliet TC, Boschker HT, Verstraete W, Van de Wiele T. 2010. Human faecal microbiota display variable patterns of glycerol metabolism. FEMS Microbiol Ecol 74:601-611. https://doi.org/10.1111/j.1574-6941.2010.00974.x
59. National Committee for Clinical Laboratory Standards. 2004. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 6th ed. National Committee for Clinical Laboratory Standards, Wayne, PA
60. Auchtung JM, Robinson CD, Britton RA. 2015. Cultivation of stable, reproducible microbial communities from different fecal donors using minibioreactor arrays (MBRAs). Microbiome 3:42. https://doi.org/10.1186/s40168-015-0106-5
61. Koenigsknecht MJ, Theriot CM, Bergin IL, Schumacher CA, Schloss PD, Young VB. 2015. Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. Infect Immun 83:934-941. https://doi.org/10.1128/IAI.02768-14
62. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC, Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205-208. https://doi.org/10.1038/ nature13828
63. Yu Z, Morrison M. 2004. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques 36:808-812
64. Salonen A, Nikkila J, Jalanka-Tuovinen J, Immonen O, Rajilic-Stojanovic M, Kekkonen RA, Palva A, de Vos WM. 2010. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J Microbiol Methods 81:127-134. https://doi.org/10.1016/j.mimet.2010.02.007
65. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402-408. https://doi.org/10.1006/meth.2001.1262
66. Savidge TC, Pan WH, Newman P, O'Brien M, Anton PM, Pothoulakis C. 2003. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 125:413-420. https://doi.org/10.1016/S0016-5085(03)00902-8
67. Spinler JK, Brown A, Ross CL, Boonma P, Conner ME, Savidge TC. 2016. Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease. Anaerobe 40:54-57. https://doi.org/10.1016/j.anaerobe.2016.05.008
68. Castillo M, Martin-Orue SM, Manzanilla EG, Badiola I, Martin M, Gasa J. 2006 Quantification of total bacteria, enterobacteria and lactobacilli populations in pig digesta by real-time PCR. Vet Microbiol 114:165-170. https://doi.org/10.1016/j.vetmic.2005.11.055
69. Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. 2004. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 97:1166-1177. https://doi.org/10.1111/j.1365-2672.2004.02409.x
70. Aagaard K, Petrosino J, Keitel W, Watson M, Katancik J, Garcia N, Patel S, Cutting M, Madden T, Hamilton H, Harris E, Gevers D, Simone G, McInnes P, Versalovic J. 2013. The Human Microbiome Project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J 27:1012-1022. https://doi.org/10.1096/fj.12-220806
71. Edgar RC. 2013. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 10:996-998. https://doi.org/10.1038/ nmeth.2604
72. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. 2010. QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7:335-336. https://doi.org/10.1038/nmeth.f.303
73. Montrose DC, Zhou XK, Kopelovich L, Yantiss RK, Karoly ED, Subbaramaiah K, Dannenberg AJ. 2012. Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia. Cancer Prev Res 5:1358-1367. https://doi.org/10.1158/1940-6207.CAPR-12-0160
74. Chumpitazi BP, Hollister EB, Oezguen N, Tsai CM, McMeans AR, Luna RA, Savidge TC, Versalovic J, Shulman RJ. 2014. Gut microbiota influences low fermentable substrate diet efficacy in children with irritable bowel syndrome. Gut Microbes 5:165-175. https://doi.org/10.4161/gmic.27923
75. Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA. 2007. Genetic progression and the waiting time to cancer. PLoS Comput Biol 3:e225. https://doi.org/10.1371/journal.pcbi.0030225
76. Reitman ZJ, Jin G, Karoly ED, Spasojevic I, Yang J, Kinzler KW, He Y, Bigner DD, Vogelstein B, Yan H. 2011. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. Proc Natl Acad Sci U S A 108:3270-3275. https://doi.org/10.1073/pnas.1019393108
77. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. 2009. Integrated, nontargeted ultrahigh performance liquid chromatography/ electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 81:6656-6667. https://doi.org/ 10.1021/ac901536h
78. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. 2013. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 57: 4872-4876. https://doi.org/10.1128/AAC.01136-13
79. Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Lesniewski RA, Oakley BB, Parks DH, Robinson CJ, Sahl JW, Stres B, Thallinger GG, Van Horn DJ, Weber CF. 2009. Introducing mothur: opensource, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 75:7537-7541. https://doi.org/10.1128/AEM.01541-09
80. Dixon P. 2003. VEGAN, a package of R functions for community ecology. J Veg Sci 14:927-930